Psoriatic arthritis: pharmacoeconomic considerations

Area of Science:

• Rheumatology
• Immunology
• Pharmacoeconomics

Background:

• Psoriatic arthritis (PsA) is a chronic inflammatory condition causing progressive joint damage and impacting quality of life.
• Traditional treatments for PsA offer symptomatic relief but do not halt disease progression.
• The advent of TNF antagonists has transformed PsA management.

Purpose of the Study:

• To evaluate the clinical efficacy and economic impact of TNF antagonists in treating psoriatic arthritis.
• To assess the role of TNF blockers in managing both musculoskeletal and cutaneous manifestations of PsA.

Main Methods:

• Review of clinical data on TNF antagonist efficacy in PsA.
• Pharmacoeconomic analysis of TNF blocker treatment in PsA.
• Assessment of impact on functional status and health-related quality of life.

Main Results:

• TNF antagonists significantly reduce inflammation, improve quality of life, and enhance functional capacity in PsA patients.
• These agents effectively hinder the progression of structural joint damage in PsA.
• Pharmacoeconomic studies confirm the cost-effectiveness of TNF blockers for PsA.

Conclusions:

• TNF antagonists represent a revolutionary and cost-effective therapeutic strategy for psoriatic arthritis.
• Despite accessibility challenges, TNF blockers offer significant clinical benefits for PsA patients.
• The use of TNF blockers is justified by their efficacy in managing PsA and their favorable economic profile.